Maximizing the erythropoietin response: Iron strategies

Peritoneal Dialysis - State-of-the-Art 2012

Volumn 178, Issue , 2012, Pages 95-99

  Prabhu, Mayoor V ^a   Nayak, Aditi ^b   Sridhar, G ^a   Subhramanyam, S V ^b   Nayak, K S ^b  

^a Global Hospital   (India)

^b Department of Nephrology and Renal Transplantation   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84862131195     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000337820     Document Type: Chapter

References (17)

1. Drueke T: Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant 2001;16:25-28.
2. Aronoff GR: Safety of intravenous iron in clinical practice: implications for anemia management protocols. J Am Soc Nephrol 2004;15:S99-S106.
3. Horl WH, Jacobs C, McDougall IC, et al: European Best Practice Guidelines: inadequate response to epoietin. Nephrol Dial Transplant 2000;15:43-50.
4. K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2006;47(5 suppl 3):S11-S145.
5. Fishbane S, Frei GL, Maesaka J: Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995;26:41-46.
6. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE: A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996;50:1694-1699.
7. Fudin R, Jaichenko J, Shostak A, Bennett M, Gotloib L: Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study. Nephron 1998;79:299-305.
8. Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S: A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 2005;68:2846-2856.
9. Feldman HI, Joffe M, Robinson B, Knauss J, Cizman B, Guo W, Franklin-Becker E, Faich G: Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 2004;15:1623-1632.
10. Harford A, Stidley C, Hunt C, Paine S, Pai A, Scavini S, Brown R, Zager P: Iron dose and survival in hemodialysis patients (abstract). J Am Soc Nephrol 2003;14:266A.
11. Hoen B, Paul-Dauphin A, Hestin D, Kessler M: EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998;9:869-876.
12. Chandler G, Harchowal J, MacDougall IC: Intravenous iron sucrose: establishing a safe dose. Am J Kidney Dis 2001;38:988-991.
13. Sridhar G: High dose intravenous iron therapy in CAPD -a safe, convenient and cost effective alternative (abstract). Perit Dial Int 2009;29:5.
14. Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD: A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysisdependent chronic kidney disease patients. Nephrol Dial Transplant 2011;26:1599-1607.
15. Provenzano R, Schiller S, Rao M, Coyone D, Brenner L, Pereira BJ: Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol 2009;4:389-393.
16. Singh AJ, Patel T, Hertel J, et al: Safety of ferumoxytol in patients with anemia and CKD. Am J Kidney Dis 2008:52:907-915.
17. Wikstrom B, Bhandari S, Barany P, et al: Monofer, a novel intravenous iron oligosaccharide for treatment of iron deficiency in patients with chronic kidney disease (CKD). World Congress of Nephrology, Milan, 2009.